Close

BIO Statement on House Energy & Commerce Committee 340B Drug Pricing Program Review

Jan 10 2018
Washington, DC (January 10, 2018) – BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

BIO Applauds Support for Innovation in Trump Administration Task Force Report

Jan 9 2018
“Biotechnology Sector is a Driver of the ‘Fourth Industrial Revolution’” Washington, D.C. (January 9, 2018) – The Biotechnology Innovation Organization (BIO) is applauding a new report from the Interagency Task Force on Agriculture and Rural Prosperity, which encourages growth and continued innovation in America’s biotechnology sector.

BIO Statement on Retirement of Senator Orrin Hatch

Jan 2 2018
Washington, DC (January 2, 2018) – “BIO joins the nation – and the great state of Utah – in applauding Senator Hatch for his many years of service, and for proving time and time again to be a strong champion for biomedical innovation."

BIO Applauds House Passage of the Corporate Governance Reform and Transparency Act

Dec 21 2017
Washington, DC (December 21, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds the House of Representatives for passing H.R. 4015, the Corporate Governance Reform and Transparency Act.  This bipartisan bill, sponsored by Reps. Sean Duffy (R-WI) and Gregory Meeks (D-NY), was approved by a 238-182 vote.

BIO Applauds USTR for Standing Up for Ag Innovation and Sound Science

Dec 14 2017
U.S. Government and 16 like-minded WTO Members Call for Implementation of the Sanitary and Phytosanitary (SPS) Agreement Washington, D.C. (December 14, 2017) – The Biotechnology Innovation Organization (BIO) is applauding efforts by the United States Government and other World Trade Organization (WTO) members for committing to strengthen the implementation and application of Sanitary and Phytosanitary Measures (SPS Agreement).  

Dynamic Speaker Lineup Announced for BIO CEO & Investor Conference

Dec 14 2017
The Biotechnology Innovation Organization (BIO) today announces preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 12-13, 2018 in New York. The program will include a diverse group of industry luminaries at the forefront of exciting science in such areas as gene therapy and new oncology treatments.

2018 RFS Volumes Set Back Growth in Cellulosic Biofuels

Nov 30 2017
BIO is disappointed that EPA did not raise the Renewable Fuel Standard's advanced and cellulosic biofuel volumes for 2018 in line with the industry’s ability to produce them.

BIO Applauds Sens. Tillis and Peters for Introducing the Fostering Innovation Act

Nov 15 2017
Washington, DC (November 15, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds Sens. Thom Tillis (R-NC) and Gary Peters (D-MI) for introducing the Fostering Innovation Act.  This vital legislation would build on the success of the JOBS Act and further reduce regulatory costs for biotech small businesses.

BIO Statement on Senate GOP Tax Reform Proposal

Nov 10 2017
Washington, DC (November 10, 2017) – Biotechnology Innovation Organization (BIO) Senior Vice President of Communications Kenneth Lisaius released the following statement regarding the Senate GOP tax reform proposal.

BIO Statement on USDA Withdrawal of 340 Biotech Rules

Nov 6 2017
The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology.  The Biotechnology Innovation Organization (BIO) issued the following statement in response: